A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment
Yan Ouyang, Yafei Zhao, M. Chen, Junru Li, Xinyi Zhu, Qing Zhao, Hong Ren, Jiali Wei, Nan Chen, Xiaoxia Pan, Jingyuan Xie
Abstract
IgA nephropathy (IgAN) is one of the most common forms of primary glomerulonephritis worldwide, especially in Asia. The diagnosis of IgAN is pathologically defined by IgA being the dominant Ig deposited in the glomerular mesangium.1 Clinically, IgAN presents with varying degrees of hematuria and proteinuria. Pitcher et al. reported that the risk of progression has been severely underestimated. Approximately 50% of patients with high-risk IgAN develop ESKD within 5.9 years, and 80% within 20 years.
Topics & Concepts
MedicineNephropathyBudesonideGastroenterologyUrologyInternal medicineIntensive care medicineEndocrinologyCorticosteroidDiabetes mellitusRenal Diseases and GlomerulopathiesSystemic Lupus Erythematosus ResearchAutoimmune Bullous Skin Diseases